Sign up for the Abwiz Bio Newsletter to get actionable advice and exclusive deals direct to your inbox.
Phospho-Stat4 (Tyr693) (F6) rabbit mAb APC conjugate
Customers Also Viewed
|Description||In response to IL-12 binding, the IL-12 receptor activates the Jak kinases, which phosphorylate tyrosine residues of IL-12Rβ2. These phosphorylated receptors recruit Stat4 through its SH2 domain, whereupon Stat4 is phosphorylated at Tyr693 in its C-terminal transactivation domain. Phosphorylation promotes Stat4 homodimerization and translocation to the nucleus, where it promotes gene transcription. The N-terminal domain of Stat4 appears to be required for maximal stabilization and for the binding of Stat4 dimers to lower-affinity DNA binding sites. Stat4-deficient mice have demonstrated that this gene is required to both promote Th1 development and inhibit Th2 differentiation due to disabling IL-12 receptor-mediated responses.|
|Please Note||We are currently experiencing technical difficulties with our website that we hope to resolve soon. For order inquiries, please e-mail firstname.lastname@example.org. International shipping is available.|
|Validated Reactivity||Human, Mouse|
|Cross Reactivity||Predicted to work with mouse, rat and other homologues.|
|Immunogen||A synthetic phospho-peptide corresponding to residues surrounding Tyr693 of human phospho Stat4|
|Formulation||1X PBS, 0.09% NaN3, 0.2% BSA|
|Recommended Usage||For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells or 5 µL per 100 µL of staining volume. It is recommended that the reagent be titrated for optimal performance for each application.|
|Pseudonyms||Signal transducer and activator of transcription 4|
|References||Kaplan MH, Sun Y, Hoey T, and Grusby MJ. (1996) Nature. 382: 174-177.
Chang H, Zhang S, Oldham I, Naeger L, Hoey T, and Kaplan MH. (2003) Journal of Biological Chemistry. 278: 32471-32477.
Flow cytometric analysis of K562 cells unstained imatinib treated cells as negative control (blue) or stained and treated with imatinib (red) or treated with IFNα + IL-4 + pervanadate (green) using phospho-Stat4 (Tyr693) antibody Stat4Y693-F6 PE conjugate. Cat #2284.